Piperidine derivatives useful as CCR5 antagonists

Details Piperidine derivatives useful as CCR5 antagonists Piperidine derivatives useful as CCR5 antagonists

2007-12-11

2007-12-11

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252110, C514S253110, C514S253130, C544S295000, C544S357000, C544S364000

Reexamination Certificate

active

10738907

ABSTRACT:
The present invention provides a compound of the formulaor a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

REFERENCES:
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5952349 (1999-09-01), Asberom et al.
patent: 5977138 (1999-11-01), Wang et al.
patent: 5994356 (1999-11-01), Pieper et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 7008946 (2006-03-01), Miller
patent: WO 02/079194 (2002-10-01), None
Vlieghe et al., Journal of Medicinal Chemistry, 2001, 44, 3014.
Cohen et al., Am. J. Clin. Pathol., 1996, 105, 589.
A-M Vandamme, et al., Anti-human Immunodeficiency Virus Drug Combination Strategies,Antiviral Chemistry&Chemotherapy9:187-203 (1998).
Bruhl et al., “Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine . . . ”, J. Immunology (2001), 166: 2420-2426.
Sellebjerg et al., “CCR5 (delta)32, matrix metalloproteinase-9 and disease activity in multiple sclerosis”, J. of Neuroimmunology (2000), 102: 98-106.
Simpson et al., “Expression of the Beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue”, J. of Neuroimmunology (2000), 108: 192-200.
Sorensen et al., “Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients”, J. of Clinical Investigation (1999), 103(6): 807-815.
Balashov et al., “CCR5 and CXCR3 T cells are increased in multiple scherosis and their ligands . . . ”, Proc. Natl. Acad. Sci. (Jun. 1999), 96: 6873-6878, Immunology.
Barcellos et al., “CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis”, Immunogenetics (2000), 51: 281-288.
Zang et al., “Aberrant T cell migration toward RANTES and MIP-1 (alpha) in patients with multiple sclerosis . . . ”, Brain (2000), 123: 1874-1882.
Schuh et al., “The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice”, The FASEB Journal (Feb. 2002), 16: 228-230.
Yang et al., “A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses”, Eur. J. Immunol. (2002), 32:2124-2132.
Loetscher et al., “Homing chemokines in rheumatoid arthritis”, Arthritis Research (2002), 4(4): 233-236.
Zapico et al., “CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis”, Genes and Immunity (2000), 1: 288-289.
Scheerens et al., “Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease . . . ”, Eur. J. Immunol. (2001), 31: 1465-1474.
Horuk et al., “Chemokine Receptor Antagonists”, John Wiley & Sons, Inc. Med. Res. Rev. (2000), 20(2): 155-168.
Fischereder et al., “CC chemokine receptor 5 and renal-transplant survival”, The Lancet (Jun. 2, 2001), 357: 1758-1761.
Murai et al., “Active participation of CCR5 CD8 T lymphocytes in the pathogensis of liver injury in graft-versus-host disease”, J. of Clinical Investigation (Jul. 1999), 104(1): 49-57.
J. Michael Kilby, “Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors”, Exp. Opin. Invest. Drugs (1999), 8(8): 1157-1170.
Mastrolorenzo et al., “Small molecule antagonists of chemokine receptors as emerging anti-HIV agents”, Expert Opin. Ther. Patents (2001), 11(8): 1245-1252.
Agrawal et al., “Chemokine receptors: emerging opportunities for new anti-HIV therapies”, Expert Opin. Ther. Targets (2001), 5(3): 303-326.

Affiliated with

Also associated with

Rating

Piperidine derivatives useful as CCR5 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine derivatives useful as CCR5 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives useful as CCR5 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3876444